AR116753A1 - Proceso de preparación de un derivado de pirazolsulfonilamida - Google Patents

Proceso de preparación de un derivado de pirazolsulfonilamida

Info

Publication number
AR116753A1
AR116753A1 ARP190102967A ARP190102967A AR116753A1 AR 116753 A1 AR116753 A1 AR 116753A1 AR P190102967 A ARP190102967 A AR P190102967A AR P190102967 A ARP190102967 A AR P190102967A AR 116753 A1 AR116753 A1 AR 116753A1
Authority
AR
Argentina
Prior art keywords
indacen
hexahydro
pyrazole
isopropyl
sulfonamide
Prior art date
Application number
ARP190102967A
Other languages
English (en)
Inventor
Thomas Alanine
Stephen Thom
Sascha Breeger
Daniel Schwizer
Original Assignee
Inflazome Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inflazome Ltd filed Critical Inflazome Ltd
Publication of AR116753A1 publication Critical patent/AR116753A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D231/08—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with oxygen or sulfur atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C201/00—Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
    • C07C201/06—Preparation of nitro compounds
    • C07C201/08—Preparation of nitro compounds by substitution of hydrogen atoms by nitro groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/45—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by at least one doubly—bound oxygen atom, not being part of a —CHO group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/30—Preparation of compounds containing amino groups bound to a carbon skeleton by reduction of nitrogen-to-oxygen or nitrogen-to-nitrogen bonds
    • C07C209/32—Preparation of compounds containing amino groups bound to a carbon skeleton by reduction of nitrogen-to-oxygen or nitrogen-to-nitrogen bonds by reduction of nitro groups
    • C07C209/36—Preparation of compounds containing amino groups bound to a carbon skeleton by reduction of nitrogen-to-oxygen or nitrogen-to-nitrogen bonds by reduction of nitro groups by reduction of nitro groups bound to carbon atoms of six-membered aromatic rings in presence of hydrogen-containing gases and a catalyst
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C211/57—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems of the carbon skeleton
    • C07C211/61—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems of the carbon skeleton with at least one of the condensed ring systems formed by three or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/45—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
    • C07C45/455—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation with carboxylic acids or their derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/657—Unsaturated compounds containing a keto groups being part of a ring containing six-membered aromatic rings
    • C07C49/665—Unsaturated compounds containing a keto groups being part of a ring containing six-membered aromatic rings a keto group being part of a condensed ring system
    • C07C49/675—Unsaturated compounds containing a keto groups being part of a ring containing six-membered aromatic rings a keto group being part of a condensed ring system having three rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/80—Ketones containing a keto group bound to a six-membered aromatic ring containing halogen
    • C07C49/813—Ketones containing a keto group bound to a six-membered aromatic ring containing halogen polycyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)

Abstract

La presente se refiere a procesos de preparación de N-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-1-isopropil-1H-pirazol-3-sulfonamida y sales de esta. La presente se refiere además a composiciones farmacéuticas que comprenden esos compuestos y al uso de esos compuestos en el tratamiento y la prevención de trastornos y enfermedades médicas, más especialmente mediante la inhibición de NLRP3. Reivindicación 1: Un proceso de preparación de N-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-1-isopropil-1H-pirazol-3-sulfonamida o una de sus sales, que comprende la etapa de poner en contacto 1-isopropil-3-(alcoxicarbonilaminosulfonil)-1-H-pirazol con 1,2,3,5,6,7-hexahidro-s-indacen-4-amina en presencia de un solvente para obtener N-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-1-isopropil-1H-pirazol-3-sulfonamida, donde R es alquilo C₁₋₆.
ARP190102967A 2018-10-19 2019-10-18 Proceso de preparación de un derivado de pirazolsulfonilamida AR116753A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1817038.1A GB201817038D0 (en) 2018-10-19 2018-10-19 Novel processes

Publications (1)

Publication Number Publication Date
AR116753A1 true AR116753A1 (es) 2021-06-09

Family

ID=64453844

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190102967A AR116753A1 (es) 2018-10-19 2019-10-18 Proceso de preparación de un derivado de pirazolsulfonilamida

Country Status (15)

Country Link
US (1) US11724988B2 (es)
EP (1) EP3867231B1 (es)
JP (1) JP7524172B2 (es)
KR (1) KR20210081363A (es)
CN (1) CN112839927A (es)
AR (1) AR116753A1 (es)
AU (1) AU2019361274A1 (es)
BR (1) BR112021007428A2 (es)
CA (1) CA3115185A1 (es)
GB (1) GB201817038D0 (es)
IL (1) IL282166A (es)
MX (1) MX2021004431A (es)
TW (1) TW202016077A (es)
UY (1) UY38425A (es)
WO (1) WO2020079207A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20190356A (es) 2017-01-23 2019-11-20 Genentech Inc Compuestos químicos como inhibidores de la actividad de la interleuquina-1
US11840543B2 (en) 2017-05-24 2023-12-12 The University Of Queensland Compounds and uses
US11370776B2 (en) 2017-07-07 2022-06-28 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
JP2020531448A (ja) 2017-08-15 2020-11-05 インフレイゾーム リミテッド 新規なスルホンアミドカルボキサミド化合物
US11926600B2 (en) 2017-08-15 2024-03-12 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
US11518739B2 (en) 2017-08-15 2022-12-06 Inflazome Limited Sulfonamide carboxamide compounds
JP2020531453A (ja) 2017-08-15 2020-11-05 インフレイゾーム リミテッド Ｎｌｒｐ３阻害剤としてのスルホニルウレアおよびスルホニルチオウレア
WO2019034692A1 (en) 2017-08-15 2019-02-21 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
EP3707134A1 (en) 2017-11-09 2020-09-16 Inflazome Limited Novel sulfonamide carboxamide compounds
WO2019166627A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
US11884645B2 (en) 2018-03-02 2024-01-30 Inflazome Limited Sulfonyl acetamides as NLRP3 inhibitors
WO2019166632A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
WO2019166629A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
WO2019166619A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
GB201806578D0 (en) 2018-04-23 2018-06-06 Inflazome Ltd Novel compound
EP3823726A1 (en) 2018-07-20 2021-05-26 F. Hoffmann-La Roche SA Sulfonylurea compounds as inhibitors of interleukin-1 activity
GB201817038D0 (en) 2018-10-19 2018-12-05 Inflazome Ltd Novel processes
JP2024508728A (ja) * 2021-02-10 2024-02-28 ハンジョウ イノゲート ファーマ カンパニー リミテッド Ｎｌｒｐ３阻害剤としての化合物
AR126215A1 (es) 2021-06-23 2023-09-27 Hoffmann La Roche Proceso novedoso
CA3242600A1 (en) 2022-02-15 2023-08-24 F. Hoffmann-La Roche Ag Processes for the preparation of 1,2,3,5,6,7-hexahydro-s-indacene derivatives
WO2024133610A1 (en) 2022-12-23 2024-06-27 F. Hoffmann-La Roche Ag Proccesses for the preparation of an nlrp3 inhibitor

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0660176B2 (ja) * 1984-03-22 1994-08-10 日産化学工業株式会社 ピラゾールスルホニルウレア誘導体、製法および選択性除草剤
GB9609641D0 (en) * 1996-05-09 1996-07-10 Pfizer Ltd Compounds useful in therapy
KR101709292B1 (ko) * 2009-11-04 2017-02-22 닛산 가가쿠 고교 가부시키 가이샤 설포닐우레아 화합물의 결정형 및 그 제조 방법
US20150112063A1 (en) * 2012-06-26 2015-04-23 Rallis India Limited Process of preparation of azimsulfuron
SG10201913603QA (en) * 2014-10-06 2020-02-27 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
US10538487B2 (en) 2015-02-16 2020-01-21 The University Of Queensland Sulfonylureas and related compounds and use of same
EP3272739A1 (en) 2016-07-20 2018-01-24 NodThera Limited Sulfonyl urea derivatives and their use in the control of interleukin-1 activity
CR20190356A (es) 2017-01-23 2019-11-20 Genentech Inc Compuestos químicos como inhibidores de la actividad de la interleuquina-1
GB201806578D0 (en) 2018-04-23 2018-06-06 Inflazome Ltd Novel compound
GB201817038D0 (en) 2018-10-19 2018-12-05 Inflazome Ltd Novel processes

Also Published As

Publication number Publication date
AU2019361274A1 (en) 2021-05-06
JP7524172B2 (ja) 2024-07-29
US11724988B2 (en) 2023-08-15
IL282166A (en) 2021-05-31
KR20210081363A (ko) 2021-07-01
GB201817038D0 (en) 2018-12-05
WO2020079207A1 (en) 2020-04-23
CN112839927A (zh) 2021-05-25
CA3115185A1 (en) 2020-04-23
BR112021007428A2 (pt) 2021-08-03
EP3867231B1 (en) 2024-05-01
UY38425A (es) 2020-05-29
MX2021004431A (es) 2021-07-06
EP3867231A1 (en) 2021-08-25
TW202016077A (zh) 2020-05-01
JP2022505189A (ja) 2022-01-14
EP3867231C0 (en) 2024-05-01
US20220064125A1 (en) 2022-03-03

Similar Documents

Publication Publication Date Title
AR116753A1 (es) Proceso de preparación de un derivado de pirazolsulfonilamida
CL2021000382A1 (es) Compuestos novedosos de sulfonamidaurea
UY37847A (es) Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
UY38001A (es) Compuestos que inhiben las proteínas ras mutantes g12c
UY38186A (es) Sal sódica de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-1-isopropil-1h-pirazol-3-sulfonamida
UY38221A (es) Inhibidores de proteínas ras con g12c mutantes
UY38602A (es) Compuestos tricíclicos condensados
CL2021000191A1 (es) Inhibidores de inflamasoma nlrp3
NI202100009A (es) Métodos para reducir la necesidad de revascu
CL2018002009A1 (es) Compuestos derivados de ciclopentanoperhidofenantreno, moduladores de fxr; composicion farmaceutica que comprende dichos compuestos; y su uso para el tratamiento de enfermedades colestásicas, fibróticas, hipercolesterolemia, entre otras.
CL2022001743A1 (es) Dosis de gamma-hidroxibutirato (ghb)
EA201892007A1 (ru) 3-дезоксипроизводное и фармацевтические композиции на его основе
DOP2019000193A (es) Nuevo compuesto heterocíclico, su método de preparación y composición farmacéutica que lo comprende
DOP2023000145A (es) Inhibidores de cdk2 y métodos de uso de los mismos
CL2021000844A1 (es) Compuestos de indolinona para uso como inhibidores de map4k1
CL2019002900A1 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
AR104068A1 (es) Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
BR112021022255A2 (pt) Composto usado como inibidor de quinase e aplicação do mesmo
CO2021011023A2 (es) Compuesto heterocíclico, composición farmacéutica que lo comprende, método para su preparación, y uso de estos
CO2022014499A2 (es) Moduladores de nlrp3
CL2018000391A1 (es) Combinaciones farmacéuticas y su uso
CO2024005925A2 (es) Moléculas pequeñas para el tratamiento del cáncer
MX2019003470A (es) Composicion farmaceutica y metodo para el tratamiento de la enfermedad del higado graso no alcoholico.
EA201990550A1 (ru) Офтальмологический препарат, включающий азоловое соединение